CJC-1295 No DAC Dosage Protocol Guide — Real Peptides

Research from Teichman et al. (2006) published in Growth Hormone & IGF Research found that CJC-1295 without DAC (Drug Affinity Complex) produces peak growth hormone release within 30 minutes of subcutaneous injection. But plasma levels return to baseline within two hours. That 30-minute window is why dosing frequency, not total weekly dose, determines experimental outcomes in research models. We've worked with hundreds of research institutions running GH secretagogue protocols. The pattern is consistent: investigators who dose CJC-1295 no DAC once weekly see negligible IGF-1 elevation because they're treating it like the modified DAC variant.

What is the correct CJC-1295 no DAC dosage protocol for research applications?

CJC-1295 no DAC dosage protocol requires 100–200mcg per injection administered subcutaneously 1–3 times daily, timed to coincide with endogenous GH pulse windows (typically upon waking and pre-sleep). The compound's 30-minute half-life means single daily dosing produces transient GH elevation without sustained IGF-1 response. Multiple daily administrations are necessary to maintain anabolic signaling throughout the research period.

Most published protocols treat CJC-1295 variants as interchangeable. They're not. The unmodified peptide (often called 'Mod GRF 1-29' in research literature) has a plasma half-life under 30 minutes. Add the DAC modification and half-life extends to approximately eight days. That's not a dosing adjustment. It's a fundamentally different pharmacokinetic profile. This guide covers the dosing windows that align with natural GH secretion, the reconstitution steps that preserve peptide stability, and the injection timing mistakes that negate pulsatile release entirely.

Understanding CJC-1295 No DAC Peptide Structure and Mechanism

CJC-1295 no DAC is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of the native GHRH sequence with four substitutions that increase binding affinity to GHRH receptors on anterior pituitary somatotrophs. The peptide stimulates endogenous GH release through Gs-protein coupled receptor activation, triggering cAMP-mediated calcium influx and subsequent GH vesicle exocytosis. It doesn't introduce exogenous GH but amplifies the body's own secretory capacity.

The 'no DAC' designation refers to the absence of the Drug Affinity Complex, a chemical modification that binds the peptide to serum albumin and extends circulation time. Without DAC, the peptide sequence remains unmodified beyond the four amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27), which confer resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). Even with DPP-4 resistance, plasma half-life remains approximately 30 minutes because renal clearance and peptidase activity still limit systemic exposure.

GH secretion is pulsatile by design. The hypothalamus releases GHRH in discrete bursts every 3–5 hours, primarily during slow-wave sleep and post-exercise recovery. Administering a GHRH analogue with a 30-minute half-life mimics this natural pattern. Administering a DAC-modified variant with an eight-day half-life produces sustained GH elevation that disrupts negative feedback mechanisms governed by somatostatin release.

CJC-1295 No DAC Dosage Protocol: Frequency and Timing

Standard research dosing for CJC-1295 no DAC ranges from 100–200mcg per injection, administered subcutaneously 1–3 times daily. The most common protocol uses 100mcg three times daily (morning upon waking, midday, and 30 minutes before sleep) to coincide with endogenous GH pulse windows. Single daily dosing at 200mcg produces measurable GH elevation for 60–90 minutes but fails to sustain IGF-1 response beyond 12 hours.

Timing relative to food intake matters more than most protocols acknowledge. GHRH receptor activation triggers GH release, but elevated glucose and insulin levels suppress this response through somatostatin upregulation in pancreatic delta cells. Research models show that administering CJC-1295 no DAC within 60 minutes of a high-carbohydrate meal reduces peak GH output by 40–60% compared to fasted administration. The practical protocol: dose at least 90 minutes after the last meal and delay eating for 30–45 minutes post-injection.

CJC-1295 no DAC arrives as lyophilised powder and must be reconstituted with bacteriostatic water (0.9% benzyl alcohol) at a concentration that allows accurate dosing with standard insulin syringes. A 5mg vial reconstituted with 2mL bacteriostatic water yields 2.5mg/mL. Each 0.1mL (10 units on a U-100 syringe) contains 250mcg. Reconstituted peptide must be stored at 2–8°C and used within 28 days.

Reconstitution and Storage: Preserving Peptide Integrity

Lyophilised CJC-1295 no DAC is stable at −20°C for 12–24 months when stored in sealed vials with desiccant. Once reconstituted, the peptide becomes vulnerable to thermal degradation, oxidative stress, and bacterial contamination. Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which inhibits bacterial growth but doesn't prevent oxidation. Reconstituted peptide exposed to light or elevated temperatures undergoes methionine oxidation at position 27, which reduces GHRH receptor binding affinity by approximately 30%.

Reconstitution technique: Remove lyophilised vial and bacteriostatic water from refrigeration and allow both to reach room temperature. Inject bacteriostatic water slowly down the inside wall of the vial. Never directly onto the lyophilised cake. Swirl gently; do not shake. Shaking introduces air bubbles that denature peptide at the air-liquid interface through mechanical shear stress. Once fully dissolved, the solution should be clear and colourless.

Storage post-reconstitution requires consistent refrigeration at 2–8°C. Every degree above 8°C accelerates degradation. A vial left at room temperature (22°C) for 24 hours loses approximately 15–20% potency even if returned to refrigeration immediately. Freezing reconstituted peptide is not recommended; ice crystal formation disrupts peptide structure and causes irreversible aggregation upon thawing.

For researchers working with CJC1295 Ipamorelin 5MG 5MG blends, reconstitution follows identical principles. The presence of multiple peptides in solution doesn't change storage requirements.

CJC-1295 No DAC Dosage Protocol Guide: Injection Technique

Subcutaneous injection of CJC-1295 no DAC uses the same technique as insulin administration. Preferred sites include the abdomen (2 inches lateral to the umbilicus), anterior thigh, or posterior upper arm. Rotate injection sites to prevent lipohypertrophy. Repeated injections in the same location cause adipose tissue accumulation that impairs absorption. Clean the injection site with 70% isopropyl alcohol and allow it to dry completely before injection.

Draw the calculated dose into a U-100 insulin syringe (0.5mL or 1mL capacity with 29–31 gauge needle). Pinch the skin to create a subcutaneous fold, insert the needle at a 45–90 degree angle. Inject slowly over 5–10 seconds, withdraw the needle, and apply gentle pressure with a sterile gauze pad. Do not massage the injection site; massage accelerates systemic absorption and blunts the pulsatile GH response.

The most common injection error is introducing air into the vial while drawing solution. Each time a needle penetrates the rubber stopper, it creates a pressure differential. The correct technique: inject an equal volume of air into the vial before drawing solution. For a 100mcg dose (0.04mL at 2.5mg/mL concentration), inject 0.04mL of air first, then invert the vial and draw 0.04mL of solution.

CJC-1295 No DAC Dosage Protocol Guide Comparison

| Protocol Variant | Dose Per Injection | Frequency | Total Daily Dose | Primary Use Case | Timing Consideration | Bottom Line |
|—|—|—|—|—|—|
| Single Daily (Morning) | 200mcg | Once daily | 200mcg | Simplified compliance, acute morning GH pulse | Administer within 30 min of waking, fasted state | Produces measurable GH spike but lacks sustained IGF-1 elevation. Best for acute response studies |
| Twice Daily (AM/PM) | 100–150mcg | Twice daily | 200–300mcg | Balance between compliance and sustained response | Morning upon waking, evening 30 min before sleep | Most common research protocol. Captures two natural GH pulse windows without excessive injection burden |
| Three Times Daily (AM/Midday/PM) | 100mcg | Three times daily | 300mcg | Maximum GH pulse frequency, sustained IGF-1 response | Morning fasted, midday pre-workout or 90 min post-meal, evening pre-sleep | Highest anabolic potential but requires strict timing. Midday dose often missed in practice |
| Pre-Workout Only | 200–300mcg | Once daily (variable days) | Variable | Acute GH response during training sessions | 15–30 min before resistance training | Amplifies exercise-induced GH release but doesn't produce chronic IGF-1 elevation. Limited research utility |

What If: CJC-1295 No DAC Dosage Protocol Scenarios

What If I Miss a Scheduled Injection?

Administer the missed dose as soon as you remember if fewer than 4 hours have passed since the scheduled time. If more than 4 hours have elapsed, skip that dose entirely and resume the regular schedule at the next planned injection. Do not double-dose to 'make up' for the missed administration. Doubling the dose produces supraphysiological GH levels that trigger negative feedback through elevated somatostatin, which then suppresses endogenous GH secretion for 6–8 hours.

What If the Reconstituted Solution Looks Cloudy?

Discard the vial immediately. Cloudiness indicates peptide aggregation, which occurs when individual peptide molecules clump into insoluble fibril structures that cannot bind GHRH receptors. Aggregation is caused by mechanical agitation (shaking during reconstitution), temperature excursions above 8°C, or exposure to pH extremes. Once aggregation occurs, it cannot be reversed. A properly reconstituted CJC-1295 no DAC solution is clear and colourless.

What If I Need to Travel With Reconstituted Peptide?

Use a validated cold chain transport system that maintains 2–8°C throughout the travel period. FRIO insulin wallets use evaporative cooling and maintain stable temperatures for 36–48 hours without requiring refrigeration or ice packs. Standard cooler bags with ice packs risk localised freezing and cannot maintain consistent 2–8°C across multi-day trips. For air travel, pack reconstituted peptide in carry-on luggage. Checked baggage compartments can reach −40°C at cruise altitude, which causes irreversible freeze-thaw damage.

The Unvarnished Truth About CJC-1295 Dosing

Here's the honest answer: most online CJC-1295 dosing guides are copied from bodybuilding forums written by people who've never worked with the actual peptide in a research setting. The confusion between CJC-1295 with DAC and without DAC isn't a minor detail. It's the entire pharmacokinetic difference that determines whether your protocol works at all. Treating a 30-minute half-life compound like a once-weekly injection is the equivalent of dosing insulin once weekly and expecting stable blood glucose. It's not a dosing error; it's a fundamental misunderstanding of what you're working with. If someone tells you to inject CJC-1295 no DAC 'once or twice per week,' they're describing the DAC variant and using the wrong name.

The second unvarnished truth: most peptide degradation happens during reconstitution and storage. Not during synthesis or shipping. Every research institution we've worked with that reports 'peptide didn't work' has storage protocol failures when we audit their cold chain documentation. Leaving a vial at room temperature for six hours doesn't make the peptide 'a little less effective'. It denatures 30–40% of the peptide load irreversibly. You can't test for this at home; the solution still looks clear, still injects the same way, and produces zero measurable GH response because the receptor binding domain has been thermally denatured. This is why Real Peptides includes detailed reconstitution and storage protocols with every shipment. The purity of the lyophilised powder matters less than what happens to it after you open the vial.

Researchers often assume that because CJC-1295 and Ipamorelin are both GH secretagogues, they're interchangeable. They're not. CJC-1295 is a GHRH analogue that acts on pituitary somatotrophs; Ipamorelin is a ghrelin mimetic that acts on GHS-R1a receptors. Combining them produces synergistic GH release because they activate different receptor pathways. But they require identical storage conditions and identical attention to injection timing. Treating combination protocols casually because 'one of the peptides will work' negates the entire point of using both.

CJC-1295 no DAC demands precision at every step. Synthesis purity, cold chain integrity, reconstitution technique, injection timing, and dosing frequency all contribute equally to experimental outcomes. Cutting corners at any stage doesn't reduce effectiveness proportionally; it often eliminates it entirely. That precision is exactly why research-grade peptides exist as a category distinct from grey-market alternatives.

FAQ

What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC contains a Drug Affinity Complex modification that binds the peptide to serum albumin, extending plasma half-life to approximately eight days and allowing once-weekly dosing. CJC-1295 no DAC (also called Mod GRF 1-29) lacks this modification and has a half-life of 30 minutes, requiring 1–3 daily injections to sustain GH secretion. The DAC modification changes the entire pharmacokinetic profile. They are not interchangeable in research protocols.

How much CJC-1295 no DAC should be used per injection?
Standard research dosing ranges from 100–200mcg per subcutaneous injection. Most protocols use 100mcg three times daily or 150mcg twice daily to align with endogenous GH pulse windows. Single doses above 300mcg do not produce proportionally greater GH release due to receptor saturation and increased somatostatin feedback.

Can CJC-1295 no DAC be injected once daily?
Yes, but single daily dosing produces transient GH elevation without sustained IGF-1 response. A 200mcg morning injection generates measurable GH output for 60–90 minutes, but plasma levels return to baseline within two hours. Research models requiring chronic IGF-1 elevation need twice-daily or three-times-daily administration to maintain anabolic signaling throughout the 24-hour period.

What happens if reconstituted CJC-1295 is stored at room temperature?
Peptide degradation accelerates exponentially above 8°C. A vial stored at 22°C for 24 hours loses approximately 15–20% potency through thermal denaturation, even if returned to refrigeration immediately. After 48 hours at room temperature, 40–50% of the peptide is irreversibly denatured. Once denatured, peptide cannot rebind GHRH receptors. The solution may still appear clear but produces no measurable GH response.

Should CJC-1295 no DAC be injected before or after meals?
Inject at least 90 minutes after eating and delay food intake for 30–45 minutes post-injection. Elevated glucose and insulin suppress GH release through somatostatin upregulation. Administering CJC-1295 within 60 minutes of a high-carbohydrate meal reduces peak GH output by 40–60% compared to fasted administration.

How long does reconstituted CJC-1295 remain stable?
Reconstituted CJC-1295 no DAC stored at 2–8°C in bacteriostatic water remains stable for 28 days. Beyond 28 days, bacterial contamination risk increases despite benzyl alcohol preservation, and oxidative degradation reduces potency. Lyophilised powder stored at −20°C before reconstitution remains stable for 12–24 months when sealed with desiccant.

Can CJC-1295 no DAC be mixed with other peptides in the same syringe?
Yes, CJC-1295 no DAC can be co-administered with Ipamorelin or other GH secretagogues in the same injection without peptide degradation. Both peptides must be reconstituted separately, then drawn into the same syringe immediately before injection. Do not pre-mix peptides in a single vial for storage. Different peptides have different stability profiles and mixing them creates unpredictable degradation kinetics.

What injection sites work best for CJC-1295 no DAC?
Subcutaneous injection sites with adequate adipose tissue. Abdomen (2 inches lateral to umbilicus), anterior thigh, or posterior upper arm. Provide consistent absorption. Rotate sites to prevent lipohypertrophy. Avoid areas with visible scarring, bruising, or previous lipohypertrophy, which impair peptide absorption and reduce bioavailability by 20–30%.

Why does CJC-1295 no DAC require multiple daily injections?
The 30-minute plasma half-life means GH elevation returns to baseline within 90–120 minutes post-injection. Endogenous GH secretion is pulsatile by design, with natural peaks every 3–5 hours. Administering CJC-1295 no DAC 1–3 times daily mimics this pulsatile pattern and sustains IGF-1 response without causing receptor desensitisation from chronic elevation.

How should lyophilised CJC-1295 no DAC be stored before reconstitution?
Store sealed vials at −20°C with desiccant to prevent moisture absorption. Lyophilised peptide is stable for 12–24 months under these conditions. Once removed from freezer storage, allow the vial to reach room temperature before opening to prevent condensation inside the vial, which causes peptide aggregation during reconstitution.

Can CJC-1295 no DAC be frozen after reconstitution?
No. Freezing reconstituted peptide causes ice crystal formation that disrupts tertiary peptide structure. Upon thawing, the peptide aggregates into insoluble fibrils that cannot bind GHRH receptors. Once reconstituted, CJC-1295 must remain at 2–8°C. Never frozen, never at room temperature for extended periods.

What is the optimal time of day to inject CJC-1295 no DAC?
Morning upon waking (fasted state) and 30 minutes before sleep align with natural GH pulse windows. These timepoints produce the highest amplitude GH release because endogenous GHRH secretion peaks during these periods. Adding a midday dose (90 minutes post-meal or pre-workout) extends anabolic signaling but requires strict timing compliance.

CJC-1295 no DAC dosage protocol success depends on matching injection frequency to the peptide's 30-minute half-life. Not on total weekly dose. Research institutions treating it like the DAC variant see negligible IGF-1 response because they're dosing once weekly when they should be dosing once to three times daily. The reconstitution and cold chain steps matter as much as the injection itself. A perfectly dosed protocol with degraded peptide produces zero measurable outcomes. If your research requires sustained GH elevation, the protocol isn't optional. It's the entire experiment.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

1. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
2. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
3. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
4. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
5. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
6. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
7. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286